Related Experiment Video
Updated: Jan 9, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Trimester-Specific Impacts of Steatotic Liver Disease on Adverse Pregnancy Outcomes: A Retrospective Cohort Study
Lei Yang1, Shuhan Yang2, Youxin Wang2
1Department of Obstetrics and Gynecology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Background And Aims:
Steatotic liver disease (SLD) is increasingly identified in pregnant populations. However, its associations with adverse pregnancy outcomes (APOs) in relation to specific trimesters remain unclear. This study aimed to evaluate the trimester-specific associations between SLD and APOs.
Methods:
This study included 3806 pregnant women from Beijing Friendship Hospital. Hepatic ultrasonography was performed to assess SLD status during the first (T1) and third (T3) trimesters. Associations between SLD and APOs were assessed using logistic regression.
Results:
The prevalence of SLD among pregnant women was 10.27%, varying across trimesters. Persistent SLD (present in both T1 and T3) demonstrated positive associations with overall APOs (OR = 1.728, 95% CI: 1.202-2.502, p = 0.003), including pregnancy-associated hypertension (OR = 1.742; 95% CI: 1.019-2.916; p = 0.038), preterm birth (OR = 2.552, 95% CI: 1.019-5.965, p = 0.037), and large-for-gestational-age neonates (OR = 1.762, 95% CI: 1.080-2.820, p = 0.020). T1 SLD (OR = 1.737, 95% CI: 1.128-2.700, p = 0.013) and persistent SLD (OR = 1.821, 95% CI: 1.282-2.600, p < 0.001) were both associated with a higher risk of caesarean section. Notably, T3 SLD was significantly associated with postpartum haemorrhage (OR = 2.154; 95% CI: 1.025-4.078; p = 0.028). A marginal association was observed between pregnancy-associated hypertension and T3 SLD (OR = 2.024; 95% CI: 0.965-3.876; p = 0.045).
Conclusion:
Persistent SLD in pregnancy is associated with an increased risk of APOs, trimester-specific assessment of SLD may facilitate risk stratification and inform clinical management. Further studies are warranted to evaluate whether lifestyle interventions can mitigate these risks.
More Related Videos
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
11:08The Use of Gas Chromatography to Analyze Compositional Changes of Fatty Acids in Rat Liver Tissue during Pregnancy
Published on: March 13, 2014
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Teratogenicity
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment